CJC-1295 DAC (5 mg Vial) Dosage Protocol

Quickstart Highlights

CJC-1295 DAC is a long-acting synthetic analog of growth hormone-releasing hormone (GHRH). The DAC (Drug Affinity Complex) modification binds reversibly to albumin, extending the peptide’s half-life to approximately 6–8 days^[1]. By stimulating pituitary GHRH receptors, CJC-1295 DAC increases GH secretion and circulating IGF-1 in a dose-dependent manner^[2]. This educational protocol presents a twice-weekly subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Reconstitute: Add 2.0 mL bacteriostatic water → 2.5 mg/mL (2500 mcg/mL) concentration.

Typical dose range: 300–1000 mcg per injection, twice weekly (gradual titration).

Easy measuring: At 2.5 mg/mL, 1 unit = 0.01 mL = 25 mcg on a U-100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and twice-weekly dosing

Standard / Gradual Approach (2 mL = 2500 mcg/mL)

Week	Per-Injection Dose (mcg)	Units (per injection) (mL)	Weekly Total
Weeks 1–2	300 mcg (0.3 mg)	12 units (0.12 mL)	600 mcg/week
Weeks 3–4	500 mcg (0.5 mg)	20 units (0.20 mL)	1000 mcg/week
Weeks 5–6	750 mcg (0.75 mg)	30 units (0.30 mL)	1500 mcg/week
Weeks 7–12	1000 mcg (1 mg)	40 units (0.40 mL)	2000 mcg/week

Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs^[1]^[2]. Once-weekly dosing is also studied; adjust frequency based on protocol requirements.

For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

Draw 2.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid foaming.

Gently swirl/roll until dissolved (do not shake).

Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Important: This guide is for educational purposes only and is not medical advice. This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.

Supplies Needed

Plan based on an 8–16 week twice-weekly protocol with gradual titration.

Peptide Vials (CJC-1295 DAC, 5 mg each):

8 weeks ≈ 3 vials (~10.2 mg total)
12 weeks ≈ 4 vials (~18.2 mg total)
16 weeks ≈ 6 vials (~26.2 mg total)

Insulin Syringes (U-100):

Per week: 2 syringes (twice weekly)
8 weeks: 16 syringes
12 weeks: 24 syringes
16 weeks: 32 syringes

Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.

8 weeks (3 vials): 6 mL → 1 × 10 mL bottle
12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
16 weeks (6 vials): 12 mL → 2 × 10 mL bottles

Alcohol Swabs: One for the vial stopper + one for the injection site each injection.

Per week: 4 swabs (2 per injection × 2 injections)
8 weeks: 32 swabs → recommend 1 × 100-count box
12 weeks: 48 swabs → recommend 1 × 100-count box
16 weeks: 64 swabs → recommend 1 × 100-count box

View Supplier

Protocol Overview

Concise summary of the twice-weekly regimen.

Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects^[1].

Schedule: Twice-weekly subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).

Dose Range: 300–1000 mcg per injection with gradual titration.

Reconstitution: 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate unit measurements.

Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Research Disclaimer